Aegros Email Format
Biotechnology ResearchNew South Wales, Australia51-200 Employees
At Aegros, we firmly believe that access to life saving therapeutic plasma therapies should be a human right - not a privilege. Our mission is to put patients first through innovation, and we plan to do using our Australian invention, Haemafrac®. Haemafrac® separates therapeutic plasma proteins using a novel electro-separation process, delivering high purity, high-yield plasma derived medical products (PDMPs). Simultaneously, Aegros is in the final stages of completing the expansion of our pilot hyperimmune facility at Macquarie Park NSW. When operational, this plant will enable the processing of >100,000L of plasma per year.